Apellis Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $40 From $50, Maintains Neutral Rating
Apellis Pharmaceuticals Analyst Ratings
Apellis Pharmaceuticals Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
Apellis Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60
Apellis Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating
UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Robust Sales and Market Expansion Potential
Optimistic Outlook: Buy Rating on Apellis Pharmaceuticals Amid Strong Syfovre Sales and Upcoming VALIANT Trial Results
Apellis Pharmaceuticals Analyst Ratings